目的：评价视网膜激光光凝联合玻璃体腔注射雷珠单抗与单纯雷珠单抗治疗视网膜分支静脉阻塞继发黄斑水肿(BRVO-ME)的远期疗效及安全性。

方法：系统检索Embase、The Cochrane Library、PubMed、中国期刊全文数据库(CNKI)、万方数据库(Wanfang Database)、维普中文科技期刊数据库(VIP)关于激光和雷珠单抗治疗BRVO-ME的随机对照临床研究文献，对纳入研究进行风险评估、提取数据指标。采用RevMan 5.3软件进行数据分析，采用漏斗图评价发表偏倚。

结果：共纳入7项研究，641眼。激光联合雷珠单抗组和单纯雷珠单抗组患者的最佳矫正视力(BCVA)在治疗后12mo\和24mo\变化均无明显差异。两组在治疗12mo\和24mo\黄斑中心凹厚度的变化无明显差异。两组在12、24mo的雷珠单抗注药次数及最终不良事件发生情况方面亦无统计学差异。

结论：激光联合雷珠单抗相较单纯雷珠单抗治疗BRVO-ME，在视力和黄斑中心凹厚度方面的远期结果无明显差异，在雷珠单抗的注药次数和安全性方面也无较大差距。

METHODS: The literatures related to randomized controlled clinical studies on the treatment of BRVO-ME with laser and Ranibizumab in Embase, The Cochrane Library, PubMed, China National Knowledge Infrastructure(CNKI), Wanfang Database and China Science and Technology Journal Database(VIP)were systematically retrieved, and the risk assessment was carried out and data indicators were extracted for the included studies. RevMan 5.3 software was used for data analysis and funnel plot was used to evaluate publication bias.

RESULTS: Totally 7 studies were included, with 641 eyes. There was no significant difference in the best corrected visual acuity(BCVA)between the laser combined with Ranibizumab group and the simple Ranibizumab group at 12mo \ and 24mo \ after treatment. There was no significant difference in central foveal thickness between the two groups at 12mo \ and 24mo \. There were no statistically significant differences in the injection times of Ranibizumab and the incidence of final adverse events between the two groups at 12mo and 24mo after treatment.

CONCLUSION: Compared with the treatment of BRVO-ME with simple Ranibizumab, there was no significant difference in the long-term efficacy of vision and central foveal thickness for the laser combined with Ranibizumab, and there was no significant difference in the injection times and safety of Ranibizumab.